Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Immunol Lett. 2014 Mar-Apr;158(1-2):57-65. doi: 10.1016/j.imlet.2013.11.021. Epub 2013 Dec 8.
Tumor draining lymph nodes form the first line of defense against tumor dissemination. Lymphocyte subpopulations activated during anti-tumor response determine the outcome of host-tumor interaction. In the present study we explored the percentages of different subtypes of CD4+ lymphocytes, including regulatory cells (TFR, CD25-, and CD25+ Treg cells), helper subsets (Th1, Th2, Th17, and Tfh cells), and the expression level of their cognate cytokines (IFNγ, IL4, and IL17) in tumor draining lymph nodes of patients with breast cancer, and compared the results between node negative (LN-) and node positive (LN+) patients. Forty seven sentinel and non-sentinel auxiliary lymph nodes with or without tumor involvement were collected from untreated breast cancer patients undergoing surgical resection. Mononuclear cells obtained from fresh homogenized lymph nodes were subjected to surface and intracellular staining by flow cytometry. The results revealed the presence of a newly identified subtype of regulatory T cells, TFR, as well as CD25- Treg cells in TDLNs of the breast cancer patients. In addition, evaluation of different helper and regulatory subgroups of CD4+ T lymphocytes showed that upon metastasis of tumor cells to lymph nodes together with the progression of the disease stage, the immune responses changed from an inflammatory to an inhibitory state, as evidenced by a reduction in pro-inflammatory and anti-tumor cytokines, IL17 and IFNγ, as well as an increase in pro-tumorigenic phenotypes, Th2 and Treg cells. This situation may provide a favorable condition for tumor growth and spread.
肿瘤引流淋巴结是抵御肿瘤扩散的第一道防线。抗肿瘤反应过程中激活的淋巴细胞亚群决定了宿主-肿瘤相互作用的结果。在本研究中,我们探索了不同亚型 CD4+ 淋巴细胞的比例,包括调节细胞(TFR、CD25- 和 CD25+Treg 细胞)、辅助亚群(Th1、Th2、Th17 和 Tfh 细胞),以及它们相应细胞因子(IFNγ、IL4 和 IL17)在乳腺癌患者肿瘤引流淋巴结中的表达水平,并将结果与淋巴结阴性(LN-)和淋巴结阳性(LN+)患者进行比较。我们从接受手术切除的未经治疗的乳腺癌患者中收集了 47 个前哨和非前哨辅助淋巴结,这些淋巴结有或没有肿瘤累及。从新鲜匀浆的淋巴结中获得单核细胞,通过流式细胞术进行表面和细胞内染色。结果显示,在乳腺癌患者的 TDLNs 中存在一种新鉴定的调节性 T 细胞亚群,即 TFR,以及 CD25-Treg 细胞。此外,对不同的辅助和调节性 CD4+T 淋巴细胞亚群进行评估表明,随着肿瘤细胞转移到淋巴结以及疾病阶段的进展,免疫反应从炎症状态转变为抑制状态,表现为促炎和抗肿瘤细胞因子 IL17 和 IFNγ 的减少,以及促肿瘤表型 Th2 和 Treg 细胞的增加。这种情况可能为肿瘤生长和扩散提供了有利条件。